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Abstract
Background: People with severe mental illnesses die up to 20 years earlier than the general population, with
cardiovascular disease being the leading cause of death. National guidelines recommend that the physical care of people
with severe mental illnesses should be the responsibility of primary care; however, little is known about effective
interventions to lower cardiovascular disease risk in this population and setting. Following extensive peer review, funding
was secured from the United Kingdom National Institute for Health Research (NIHR) to deliver the proposed study. The
aim of the trial is to test the effectiveness of a behavioural intervention to lower cardiovascular disease risk in people with
severe mental illnesses in United Kingdom General Practices.
Methods/Design: The study is a cluster randomised controlled trial in 70 GP practices for people with severe mental
illnesses, aged 30 to 75 years old, with elevated cardiovascular disease risk factors. The trial will compare the effectiveness
of a behavioural intervention designed to lower cardiovascular disease risk and delivered by a practice nurse or healthcare
assistant, with standard care offered in General Practice. A total of 350 people will be recruited and followed up at 6 and
12 months. The primary outcome is total cholesterol level at the 12-month follow-up and secondary outcomes include
blood pressure, body mass index, waist circumference, smoking status, quality of life, adherence to treatments and
services and behavioural measures for diet, physical activity and alcohol use. An economic evaluation will be carried out
to determine the cost effectiveness of the intervention compared with standard care.
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Discussion: The results of this pragmatic trial will provide evidence on the clinical and cost effectiveness of the
intervention on lowering total cholesterol and addressing multiple cardiovascular disease risk factors in people with
severe mental illnesses in GP Practices.
Trial registration: Current Controlled Trials ISRCTN13762819. Date of Registration: 25 February 2013.
Date and Version Number: 27 August 2014 Version 5.
Keywords: Primary care, Severe mental illnesses, Cardiovascular risk
Background
People with severe mental illness (SMI), defined as
schizophrenia, bipolar disorder and other nonorganic
psychotic conditions, constitute 0.5 to 1 % of the United
Kingdom population [1, 2]. The National Health Service
(NHS) expenditure on mental health in 2012 to 2013
was £11.5 billion, higher than any other health category
[3]. The predicted cost to the public health sector of
schizophrenia is £7.6 billion, with the cost to society at
£11.8 billion [4]. These disorders frequently present in
the early to mid-twenties and have a major impact on
health and social functioning. Whilst the employment
rate for all adults aged 16 to 64 years in England is cur-
rently 71 %, recent estimates place the employment rate
for people with schizophrenia between 5 and 15 % [5].
People with SMI are more likely to die prematurely
from cardiovascular disease (CVD) than suicide [6–9].
CVD rates are falling in the general population but not
for people with SMI [10, 11]. This widening health in-
equality is an NHS priority, emphasised in the National
Institute for Health and Care Excellence (NICE) schizo-
phrenia and bipolar guidelines [12, 13]. CVD is one of
the most important physical health problems experi-
enced by people with SMI. Those aged under 50 years
are three times more likely to die from CVD, whereas
those aged 50 to 75 years have a twofold increased risk
[8]. These risks remain high after the effects of smoking
and social deprivation are controlled for in the analysis.
There are likely to be multiple reasons for increased
CVD in people with SMI. Research in general practice
has demonstrated increased levels of cardiovascular risk
factors including smoking, obesity, diabetes and dyslipi-
daemia in people with SMI compared to general practice
controls [14]. This included raised total cholesterol and
low density lipoprotein (LDL) cholesterol levels and
lower levels of high density lipoprotein (HDL) choles-
terol. Research has also found a higher proportion of
people with SMI eat a diet higher in fat, lower in fibre
and may be less likely to take even mild to moderate ex-
ercise [15]. A higher prevalence of increased CVD risk
factors has been demonstrated at illness onset [16] and
later in treatment [17].
The adverse effects of antipsychotic medication are a
concern for both people with SMI and practitioners. The
most effective and most commonly prescribed treat-
ments are associated with weight gain and abnormalities
of both lipid and glucose metabolism [18, 19]. The anti-
psychotics most strongly implicated are olanzapine and
clozapine, but nearly all antipsychotics can have effects
on appetite, weight gain and metabolism.
Most people with SMI are in contact with primary
care and consult with General Practitioners (GPs) more
frequently than people without SMI [9, 20], yet they are
less likely to see a practice nurse [21]. NICE recom-
mends routine annual screening for CVD risk factors for
people with both schizophrenia and bipolar disorder in
primary care [12, 13], and individuals prescribed antipsy-
chotics should receive more frequent monitoring [22].
Clinics for CVD screening in other long-term conditions
are routinely carried out by nurses in primary care.
Training practice nurses to carry out physical health
screening in people with SMI in England has the poten-
tial to increase the level of screening and lifestyle advice
received by people with SMI [23, 24].
The UK primary care quality outcomes framework
(QoF) remunerates GPs for providing an annual review
to people with SMI. The required content of such re-
views has varied over the last few years with glucose and
lipid measurements being retired in 2014/15. Research
has shown that if people with SMI are offered CVD
screening, they are as likely to take up the offer as
people without SMI [25, 26].
Although there is strong evidence for relatively high
rates of CVD deaths and CVD risk factors in people
with SMI, high quality evidence on CVD risk-reduction
strategies is lacking. Strategies might include intervening
earlier and more assertively than is currently recom-
mended for the general population. Statins have been
found to reduce CVD risk by up to 33 % in the general
population [27]; however, we have limited evidence on
the clinical effectiveness of existing treatments such as
statins for people with SMI and whether they adhere to
them. Statins have shown some promise in the short-
term reduction of severe dyslipidaemia in people with
SMI. An open, non-randomised study of statin therapy
for 52 people with severe dyslipidaemia showed signifi-
cant improvement in lipid levels at 12 weeks compared
with 48 people not receiving statins [28]. Similarly, a
Osborn et al. Trials  (2016) 17:80 Page 2 of 12
pilot randomised controlled trial of Pravastatin identified
a significant decrease in total cholesterol and LDL chol-
esterol in people with SMI; however, the effects were
much smaller than in the non-randomised study de-
scribed above, and this effect did not remain significant
at 12 weeks [29].
Clinical trials of smoking cessation in people with SMI
show small effects [30]. A Cochrane systematic review of
reducing weight gain in people with SMI revealed little
high quality evidence [31], with a handful of small stud-
ies showing modest effectiveness for pharmacological
and behavioural interventions. A systematic review
found that non-pharmacological interventions produced
a 3.12 kg reduction in body weight [32]. Most studies,
however, are short, lack statistical power, and many are
not randomised. A longer, randomised effectiveness
study is required to determine whether the impact of
CVD risk reducing strategies can be maintained.
Study objectives
The aim of the study is to test the clinical effectiveness and
cost effectiveness of a behavioural intervention to lower
CVD risk in primary care delivered to people with SMI.
The primary objective is to establish the effectiveness
of the intervention in reducing total cholesterol over a
12-month period compared with treatment as usual
(TAU).
The secondary objectives are to determine whether the
intervention accomplishes the following:
1. reduces glycated haemoglobin (HbA1c), blood
pressure, body mass index (BMI), waist
circumference, total cholesterol/HDL cholesterol
ratio, HDL cholesterol, and LDL cholesterol;
2. lowers cardiovascular risk scores;
3. increases physical activity, improves diet, reduces
the number of cigarettes smoked and reduces
alcohol intake;
4. increases the uptake of statin medications and
adherence to statin regimens; and
5. increases satisfaction with services, wellbeing and
quality of life.
We also aim to establish the cost-effectiveness of the
intervention while considering both the costs of the
intervention itself and other direct health care costs.
Methods/Design
The study is a two arm cluster-randomised controlled trial
in United Kingdom primary care services with people who
have a diagnosis of SMI, are aged 30 to 75 years old and
who have elevated CVD risk factors. GP practices will be
randomised to provide either a 6-month CVD risk reduc-
tion intervention or usual care. The cluster design will
decrease the likelihood of contamination by participants
in the TAU arm receiving the benefits of the intervention
through access to their practice nurse or healthcare assist-
ant who has been trained in assertively reducing CVD risk
for people with SMI.
Recruitment
Recruitment of GP practices
Recruitment of 70 GP practices across both rural and
urban areas of England will be coordinated in six waves.
In the first wave, we will recruit eight GP practices in
North London that will act as a pilot of the research
procedures. Any problems will be considered and, if ne-
cessary, the trial will be modified for the remaining re-
cruitment waves. Ten to 15 general practices will then
be recruited per wave. GP practices will first be
approached by local clinical research networks (CRNs)
and asked to submit an expression of interest to the
study team. Any interested practices will then be asked
to complete a site feasibility questionnaire to ensure that
they have a practice nurse or healthcare assistant who
can assess patient eligibility and deliver the intervention
if randomised, and a mental health register of 40 or
more patients. A site initiation visit will then be ar-
ranged by the central study team. All staff involved in
the study at the practice and the research nurse from
the local clinical research network, who will be taking
informed consent and collecting outcome data from par-
ticipants, will be invited to attend this meeting.
Recruitment of participants
In each recruited GP practice, all people with a relevant
diagnosis of SMI (see participant inclusion criteria) who
have not had a CVD health check in the last 12 months
will be invited to a screening appointment over an 8-
week period with a practice nurse or healthcare assistant
(HCA) who has been identified to work on the study. In-
dividuals will be screened for CVD risk, to include
current smoking status, lipid profile, blood pressure,
HbA1c and BMI. At the initial appointment, people with
SMI will be asked by the practice nurse or HCA if they
would like to receive further information about the study
should they meet inclusion criteria. When screening re-
sults are received by the practice, if they are of immediate
concern, the nurse/HCA will liaise with the GP. Other-
wise, if an individual is eligible for the trial, the results will
be handled by the nurse/HCA in a 6 to 8-week period,
after the nurse/HCA has been informed of treatment allo-
cation. The recruitment process is summarised in Fig. 1.
Practices will also search their electronic medical
records to identify individuals who have had a health
check in the last 12 months and who are potentially
eligible for the study. These people will be sent a
study invitation letter by the practice which includes
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a reply slip, study leaflet and freepost practice-
addressed envelope. Practices will then follow-up
non-responders by telephone to check if the informa-
tion has been received and to determine whether or
not the person is interested in participating. An up-
to-date health check will be arranged either by the
practice or the research nurse for all interested indi-
viduals for whom eligibility criteria were recorded
more than 3 months previously to ensure that they
are still currently eligible for the study.
Participant inclusion criteria
Inclusion criteria are adults on each participating GP
Practice mental health register with a diagnosis of SMI
(schizophrenia, persistent delusional disorder, schizoaf-
fective disorder, bipolar affective disorder, psychosis,
psychotic depression or other psychotic disorder), aged
30 to 75 years old with a total cholesterol level above
and including 5.0 mmol/l OR raised total cholesterol/
HDL cholesterol ratio above and including 4 AND one
or more of the following risk factors:
1. BMI ≥ 30 kg/m2
2. Current smoker
3. Blood pressure ≥ 140 mm Hg systolic AND/OR ≥
90 mm Hg diastolic
4. HbA1c of 42 to 47 mmol/mol (6.0 to 6.4 %) and/or
impaired fasting glucose (5.5 to 6.9 mmol/L)
5. Diagnosis of diabetes
6. Diagnosis of hypertension
Individuals must also be able to give written informed
consent and give their initial consent to be contacted by
a researcher.
Randomisation
Identify potentially eligible 
SMI patients who have had 
a CVD health check in the 
past 12 months
TAU ARM
Train nurses in CVD risk 
lowering intervention 
6 & 12 month follow up =  
140 participants (Expected 
20% attrition)  
TaU + British Heart Foundation 
leaflets sent to patients
6 & 12 month follow up =  
140 participants (Expected 
20% attrition) 
6-8 week screening period and initial consent of those potentially eligible for 
trial. Up to date eligibility screen for patients whose values were recorded 
longer than 3 months previously
Recruitment of General 
Practices (n=70) 
Invite people with SMI for a  
CVD health check who have 
not had a health check in the 
past 12 months
INTERVENTION ARM
35 General Practices
2-8 participants each = 175
Active reviews, behavioural 
interventions and statin therapy and 
monitoring of attendance and adherence
over a 6 month period.
35 General Practices
2-8 participants each = 175
Treatment as usual over a 6 month period.
Fig. 1 Flow chart of participant recruitment in the PRIMROSE trial
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Exclusion criteria
Exclusion criteria include the following:
1. Under acute psychiatric care (for example, currently
a psychiatric hospital inpatient or under the care of
a crisis team)
2. Primary diagnosis of an organic mental health
problem and/or severe cognitive impairment
3. Life expectancy < 6 months (diagnosis of metastatic
cancer or on the palliative care register)
4. Pre-existing CVD
5. Currently pregnant
6. Personality disorder or depression/anxiety without
any psychotic features
We will not specifically exclude people who already re-
ceive statins if their lipids remain raised at the initial
screening, since they still require monitoring and further
risk reduction.
Consent and research assessments
Initial agreement to be contacted by a researcher from
the local clinical research network will be obtained from
individuals either at their screening appointment with
the practice nurse/HCA or through the return of a reply
slip to the GP practice sent to people who are already
potentially eligible. If an individual does not respond to
this letter, the GP practice will call them and ask
whether they would be interested in receiving further in-
formation about the study from a research nurse. The
researcher will then telephone each eligible and inter-
ested person to explain the study in detail and to deter-
mine whether they want to take part or not, answer any
questions and arrange to obtain full written consent and
a full baseline assessment. It will be explained that the
individual is free to withdraw from the study at any time
without having any effect on their care. If a participant is
randomised to the intervention group and no longer
wishes to attend the intervention appointments, he/she
will still be invited to attend the follow-up assessments.
Written informed consent will be obtained from each
participant before the baseline assessment begins. Base-
line data will be collected by the researcher from the
participant’s medical records and through interviews and
participant self-complete questionnaires with all re-
cruited participants at the start of the study. Outcome
data will be collected at 6 and 12 months during the trial
period. Participants will be allocated a unique study
identification number, and data will be entered anonym-
ously by researchers using a web-based system set up by
Sealed Envelope [33]. It has range checks, consistency
checks and for closed questions gives a number of op-
tions plus “other” where appropriate. Researchers who
will be entering the data will have no access to the group
allocation through this system. With these checks in
place, there should not be any issues with illegal values
or inconsistent data being entered, so necessary cleaning
should be minimal. Data will be checked by the trial
statistician before analysis and any problems reported to
the trial manager, who will liaise with the researchers to
rectify them as appropriate before data analysis.
Participants will be reimbursed £20 at baseline, £10 at
the 6-month follow up and £20 at the 12-month follow-
up to thank them for their time and to cover any trans-
portation costs. Postcards will be sent after each data
collection point to thank participants for their involve-
ment in the study and remind them that follow-up will
occur later in the year.
Blinding
The trial will not be blind because masking of the partic-
ipants, practice nurses/HCAs and GPs to the treatment
allocation is not possible. The primary outcome - total
cholesterol - is objective, and researchers collecting out-
come data will be blinded to participant allocation. The
randomisation variable will be held separately to the main
body of data and will be given to the statisticians and
health economists without labels so they remain blind to
allocation when they are ready to analyse the data.
Randomisation
GP practices will be randomised to intervention or to treat-
ment as usual on a 1:1 basis by a statistician not otherwise
involved in the programme based at the University College
London PRIMENT Clinical Trials Unit. The trial man-
ager will communicate the results of randomisation to
the practices.
There should be the same number of GP practices re-
cruited to the intervention and usual care. This will be
achieved using block randomisation. The size of the
blocks is at the discretion of the independent statistician,
who will not divulge this to the trial management group,
senior statistician, trial statistician or health economists
until the allocation code is broken and the information
is needed to write up the trial. Figure 1 demonstrates
the recruitment pathway through the study.
Intervention arm
In the National Institute for Health Research (NIHR)-
funded PRIMROSE programme we performed a range of
work to inform the development of the PRIMROSE
intervention. We consulted with experts in the fields of
cardiovascular health, psychiatry and health psychology
to ensure the intervention encompasses the most con-
temporary evidence, and that it was acceptable to people
with SMI and health professionals. We have updated lit-
erature searches and run focus groups with stakeholders
to ensure that the timing, content and delivery of the
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intervention are appropriate. We conducted focus
groups with primary care nurses, people with SMI,
carers, mental health experts and GPs [34]. We also
benefited from a Lived Experience Advisory Panel
(LEAP), which provided feedback on the intervention
and associated materials [35].
Focus group interviews were underpinned by two
complimentary theoretical models, the COM-B model
[36] and the Theoretical Domains Framework (TDF)
[37]; both have been used to identify influences on pa-
tient and health professional behaviour [38]. These find-
ings were mapped to a theoretical framework of
behaviour change, the Behaviour Change Wheel [36] to
determine eight key behavioural strategies for practice
nurses/HCAs to use when working with people with SMI
to help reduce their CVD risk. These eight behavioural
change strategies form the basis of the intervention man-
ual and training programme and include goal-setting,
making an action plan, recording progress, providing posi-
tive feedback, involving supportive others, reviewing pro-
gress, coping with setbacks and habit formation.
The training will take place over 2 days (with a 2-week
gap in between each training session to enable rehearsal
of skills) with opportunities for telephone supervision.
Training day one includes the following sessions: i) the
reasons for increased cardiovascular risk in people with
severe mental illness; ii) severe mental illness symptoms,
treatments and lived experience; iii) evidence on how
the intervention manual and training programme were
developed; iv) how to deliver the PRIMROSE intervention
and use the PRIMROSE manual; and v) how to deliver the
eight behavioural change strategies in consultations with
recruited patients. Nurses and HCAs will then be asked to
implement what they have learned with a recruited pa-
tient. Training day 2 is then an opportunity to feedback
any problems, anything that went well and to practice and
revisit the skills learned on training day 1.
The training will be delivered by members of the re-
search team, a nurse with primary care and mental
health expertise, and a lived experience trainer. The
intervention has been documented in a written manual
and will be distributed to practice nurses/HCAs. The
nurse/HCA will be asked to record all of their work in-
cluding appointment attendance, clinical measures and
monitoring of health goals, and all consultations will be
audio recorded. A sample of 20 % of the recordings will
be transcribed and analysed to assess for fidelity to the
manual using an adaptation of a reliable fidelity assess-
ment method that has been developed for behavioural in-
terventions including physical activity interventions [39].
Participants in the GP practices allocated to the inter-
vention will be offered weekly to fortnightly appoint-
ments with the practice nurse/HCA over a period of
6 months. Progress with CVD risk reduction will be
reviewed at each consultation. Appointments will de-
crease to monthly if satisfactory progress is made with
reducing CVD risk. There will be flexibility over the de-
livery of the intervention depending on each individual’s
preferences and needs; however, the intervention will in-
clude one or more of the following elements:
1. Setting and monitoring participant-led behavioural
goals aimed at lowering CVD risk (for example,
improving adherence to statins or other CVD risk
lowering medications, improving diet, increasing
physical activity, reducing smoking and/or alcohol
consumption.
2. Use of a health plan to formulate a health goal and
action plan and record progress with achieving the
identified health goal.
3. Sign-posting to services such as smoking cessation
or physical activity programmes.
4. Statin prescriptions to people whose CVD risk or
lipids exceed recommended thresholds. The choice
of statin will follow local and national treatment
guidelines for statin prescribing. Current NICE
guidance advises initial treatment with atorvastatin
20 mg unless there are drug interactions or
contraindication [27]. Active monitoring of
adherence to medication and response will be
carried out.
5. Prescription of other medications such as nicotine
replacement therapy for smoking cessation, anti-
hypertensives for raised blood pressure or metformin
for diabetes and weight loss. Again active monitoring
of adherence, side effects and response will be
carried out.
6. Involvement of carers and mental health key
workers in monitoring adherence, supporting
attendance at appointments and supporting a
healthy lifestyle.
Treatment as usual arm
Practice nurses/HCAs in the standard care arm will not re-
ceive training. It will have been booked in their diaries, but
they will be informed of allocation to the standard care
arm, cancelling the training session. They will be sent
British Heart Foundation leaflets [40] to distribute to par-
ticipants. They will not be asked to review participants, to
check adherence or arrange statin prescriptions. At best,
we envisage that treatment as usual, will comprise of an in-
vitation to attend an annual health check to screen for
smoking, blood pressure, alcohol use and BMI; however,
the intensity of usual care will vary depending on the pa-
tient’s health needs. Practice nurses/HCAs in the treatment
as usual arm will be offered the opportunity to attend a
training session once the intervention period is complete.
Usual procedures of care for patients are permitted.
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Measures
The primary outcome measure is total cholesterol at 12-
month follow-up. A blood sample will be collected at
baseline using usual GP practice equipment and proce-
dures. Bloods are normally taken by the practice nurse
or HCA and sent to the local NHS hospital Trust la-
boratory for analysis. Results are then received electron-
ically through the participant’s medical record. The
blood test will be repeated at 6 and 12-month follow up
by a clinical research network nurse and processed using
usual GP practice procedures described above.
The baseline data described below will be collected ei-
ther directly from participant interviews/clinical mea-
sures or from the GP practice medical records.
Demographics
Demographic data including age, sex, marital status, em-
ployment status, ethnicity, Townsend deprivation score
calculated using each participant’s postcode, mental
healthcare worker details, whether or not the participant
is on the Care Programme Approach (CPA), and
whether they have a support worker or carer will be col-
lected for each participant.
Clinical measures
Clinical measures including blood pressure, HbA1c and
lipids (HDL, Total/HDL ratio and LDL) will be mea-
sured using usual practice procedures. Other clinical
measures include waist circumference, 10-year CVD risk
scores (QRisk) [41], Framingham re-estimated on the
UK population [42], and the PRIMROSE CVD risk pre-
diction model [42], BMI, physical co-morbid conditions,
and diagnosis of SMI confirmed by the GP practice
medical record.
We will also ask participants at the baseline assess-
ment if they would consent to providing a saliva sample
for storage at UCL laboratories or collaborating centres
in the UK and internationally for future genetic research.
This will be used to determine whether there is any
DNA variation relevant to mental health diagnosis and
physical health outcomes. Participants will be given the
opportunity to opt out of providing this saliva sample if
they wish. It will not affect their entry into the trial.
Behavioural measures
CVD risk-lowering behaviours will be assessed through a
validated self-report questionnaire on physical activity
(IPAQ) [43] and validated researcher administered ques-
tionnaires on dietary intake (DINE) [44] and alcohol use
(AUDIT-C) [45]. Each participant will also be asked their
smoking status, and, if they are a current smoker; how
many cigarettes they smoke a day.
The Morisky Scale of Adherence (MMS), a validated
self-report questionnaire [46] will be completed twice at
each time point by each participant. Participants will
first be advised to complete the questionnaire while
thinking about their psychiatric medications (for ex-
ample, antipsychotics and mood stabilisers) and secondly
in relation to any CVD risk-lowering medications they
are currently prescribed (for example, statins, anti-
hypertensives and/or stop smoking aids).
Quality of life and wellbeing
Quality of life will be measured through the EQ-5D-5 L,
a validated self-report questionnaire [47], Well-being will
be assessed using the self-report Warwick Edinburgh
Mental Wellbeing Scale (WEMWEBS) [48].
Economic measures
Economic measures will be collected from the medical
records at baseline and 12-month follow-up, including
medications used in the 12-months prior to baseline and
any new prescriptions during the study follow-up period.
General and psychiatric hospital admissions, Accident
and Emergency (A&E) contacts, outpatient visits, pri-
mary care contacts and community service use in the
previous 12 months will all be collected from the med-
ical records. In addition, participants will self-complete
an adapted Client Service Receipt Inventory (CSRI) to
collate additional information on service use, which is
unlikely to be recorded in the medical records (for ex-
ample, informal care arrangements, living situation,
CVD risk-lowering service use external to the NHS, such
as weight-management programmes, gym and leisure ac-
tivities, and community service use [49].
Follow-up assessments
Follow-up assessments will be conducted at 6 and
12 months and will include all clinical measures, behav-
ioural measures, quality of life and economic measures.
At 12 months, we will additionally collect information
on adherence to the PRIMROSE intervention appoint-
ments and client satisfaction using the Client Satisfac-
tion Questionnaire - (CSQ) [50].
A table summarising all outcome measures and data
collection time points can be found in Table 1.
Statistics and data analysis
Sample size
A total of 350 people from 70 GP practices will be re-
cruited in to the study. In determining the size of the
trial, we considered 1) important effect sizes, 2) size of
clusters, and 3) attrition.
Effect size
Our primary outcome is total cholesterol. Two commu-
nity studies of UK adults with SMI reveal mean total
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cholesterol levels of 5.4 mmol/l (standard deviation (SD)
1.3) [14] and 5.7 mmol/l (SD 1.4) [51].
We consider an effect size of 0.4 SDs difference in
cholesterol, between the two trial arms, to be the mini-
mum clinically important difference. Statins usually have
far greater effect sizes, approaching two SDs [52], how-
ever in this effectiveness trial, we are comparing a be-
havioural intervention with treatment as usual, so
cannot expect effects as large as this. Based on a two-
sample t-test, to detect a difference of 0.4 x (1.3 mmol/l)
requires 132 participants per arm, with 90 % power and
5 % significance level.
Sample size inflation for clustering and attrition
To account for the cluster effect, we have assumed that
five participants on average will be recruited per prac-
tice. Dropout rates in the SMI trials are <20 % at
12 months [30, 53]. Using an intra-class correlation coef-
ficient of 0.02 for trials in primary care [54] and an
average cluster size of four participants per practice
(after allowing for 20 % attrition) yields 140 participants
per arm. Inflating this figure for 20 % attrition and
rounding up results equates to a total of 350 participants
and 70 GP practices for the trial.
Statistical analysis
All analyses will be on an intention-to-treat basis. Statis-
tical analyses will be carried out using Stata [55]. We will
produce summary statistics for all variables, both overall
and by randomised group. Summary statistics for continu-
ous variables will be mean or median, (with SD, or inter-
quartile range) as appropriate, and for categorical variables,
frequency and percentage within each category.
The primary outcome will be analysed using a linear
random effects regression model adjusting for the base-
line cholesterol, whilst accounting for clustering as a
random effect (GP practice). Results will be presented as
Table 1 Summary of baseline and follow-up measures
Measure Source data 0 mth 6 mth 12 mth
1. Clinical measures
Total cholesterol (mmol/l) Blood test ✓ ✓ ✓
HDL, LDL, Total cholesterol/HDL ratio (mmol/l) Blood test ✓ ✓ ✓
HBA1c (mmol/mol, %) Blood test ✓ ✓ ✓
Systolic and diastolic blood pressure (mm/hg) Clinical assessment ✓ ✓ ✓
2. Anthropometric measures
BMI (kg/m2) Clinical assessment ✓ ✓ ✓
Waist circumference (cm) Clinical assessment ✓ ✓ ✓
3. Behavioural measures
Alcohol intake (AUDIT-C) Researcher administered questionnaire ✓ ✓ ✓
Smoking status Researcher administered questionnaire ✓ ✓ ✓
Diet (DINE) Researcher administered questionnaire ✓ ✓ ✓
4. Medical records.
Active physical health conditions Medical records ✓ ✓
Service use (inpatient hospital stays, outpatient appointments,
accident and emergency attendances, community service use,
health checks and action plans)
Medical records ✓ ✓
Prescribed medications Medical records ✓ ✓
CVD risk scores Medical records ✓ ✓
Scheduled appointments not attended Medical records ✓ ✓
5. Patient questionnaires
Service use: Employment, Housing, Health and Leisure (EHHaL) Patient self-report questionnaire ✓ ✓ ✓
International Physical Activity Questionnaire (IPAQ) Patient self-report questionnaire ✓ ✓ ✓
Quality of life: EQ-5D-5 L Patient self-report questionnaire ✓ ✓ ✓
Wellbeing: The Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) Patient self-report questionnaire ✓ ✓
Morisky Scale of Adherence (MMS): Psychiatric medications Patient self-report questionnaire ✓ ✓ ✓
Morisky Scale of Adherence (MMS): CVD preventative medications Patient self-report questionnaire ✓ ✓ ✓
Client Satisfaction Questionnaire - CSQ Patient self-report questionnaire ✓ ✓ ✓
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mean difference between randomised arms with 95 %
confidence interval and P value.
Appropriate analogous random effects regression
models will be used to analyse the secondary outcomes.
For both the primary and continuous secondary out-
comes, the residuals will be checked for normality. If
they are not normally distributed, outcomes may be
transformed. If it is necessary to categorise outcomes, it
will be done with clinical input.
Complete case analyses will be the main analyses from
this study. Bias due to missing data will be investigated.
A supportive analysis will include adjusting for predictors
of missingness that are related to outcome, if necessary,
and adjusting for factors that have baseline imbalances
that are related to the outcome. If the proportion of non-
adherence is greater than 5 %, an appropriate analysis ac-
counting for non-adherence will be considered. Those in
the treatment-as-usual practices will be assigned an adher-
ence score equivalent to no adherence to the intervention.
If it is appropriate to carry out this analysis, it will be done
once the statistician has been unblinded to randomised
group. Results from the analysis of secondary outcomes
and supportive analyses will be presented as estimates
with 95 % confidence intervals.
Economic evaluation
The aim of the economic evaluation is to report the mean
incremental cost of the PRIMROSE intervention com-
pared to treatment as usual in the reduction of CVD risk
in people with SMI, from the NHS perspective in the pri-
mary analysis and from a societal perspective in a second-
ary analysis. The primary effectiveness outcome, as
recommended by NICE, will be quality-adjusted life years
(QALYs) [56]. Responses to the EQ-5D-5 L questionnaire
collected during the trial will be used in conjunction with
EQ-5D-5 L specific valuation sets [47] to calculate utility
scores over a time horizon of 1 year. Baseline differences
in utility scores will be adjusted for using regression ana-
lysis. The cost of the intervention will include the cost of
the printed materials, training, clinical tests and other
consumables used during the intervention and nurse/
HCA time spent delivering the intervention. The cost-
components that will be included in the health care per-
spective analysis for arms of the trial include new pre-
scriptions during the study follow-up period, general and
psychiatric hospital admissions, A&E contacts; outpatient
visits, primary care contacts and community service use.
Informal care arrangements, changes in living situation,
carer costs, and out-of-pocket costs for services such as
weight-management programmes, gym and leisure activ-
ities, smoking cessation and community service use [48]
will be included in the societal perspective analysis. Unit
costs will be obtained from the Personal Social Services
Research Unit (PSSRU) [57], reference costs [58], British
National Formulary (BNF) [59] and other national sources
of costing information. Cost-effectiveness will be reported
as the mean incremental cost per QALY gained of the
PRIMROSE intervention versus treatment as usual. All
cost-effectiveness analyses will conform to the recom-
mended methodology [56]. Bootstrapping will be used to
derive 95 % confidence intervals for mean cost and QALYs
for the two trial groups, 95 % confidence intervals around
the incremental cost-effectiveness ratios and cost-
effectiveness acceptability curves and cost-effectiveness
planes. The analyses will be subjected to one-way and
two-way sensitivity analyses to test any assumptions made
in the analysis. Trial results will also be used to update a
long-run CVD cost-effectiveness model, extrapolating
costs and consequences to a 10-year time horizon using
discrete event-simulation.
Research governance
We will work with the Clinical Research Networks
(CRNs) to identify expressions of interest from GP prac-
tices to take part in the study.
A trial management subgroup will meet monthly at
the start of the trial to monitor progress. At trial month
3, the group will review the effectiveness of research
procedures in the first wave of practices and amend the
protocol if necessary. Meetings will decrease to 3-
monthly from month 18 of the trial onwards. There will
also be an externally chaired trial steering committee
meeting twice per year.
The trial will be fully registered and managed through
the PRIMENT clinical trials unit (http://www.ucl.ac.uk/
pcph/priment), which specialises in trials in mental
health and primary care. PRIMENT will oversee the de-
sign, randomisation of practices, web-based data entry,
all trial monitoring and the analysis plan. Data manage-
ment will also be overseen by the PRIMENT clinical tri-
als unit, with data being held for a minimum of 20 years
from completion of the study according to University
College London requirements.
Adverse events
All GP practices and research nurses will be trained in
reporting adverse events procedure. If an event occurs,
they will be instructed to telephone the trial manager
within 24 hours of becoming aware of the event. They will
then be asked to complete an adverse event form and sub-
mit this to the trial manager. Adverse events will be
assessed by the chief investigator, considered at trial man-
agement team meetings and reported to the study sponsor.
Ethics approval
Ethics approval was obtained from the City Road and
Hampstead Research Ethics Committee (Reference No:
12/LO/1934, approval granted 10 January 2013). Local
Osborn et al. Trials  (2016) 17:80 Page 9 of 12
NHS approvals are being obtained before the start of
each recruitment wave from the following research and
development (R&D) departments: North and Central
London research consortium (Noclor), Wessex primary
care research support service, Northamptonshire re-
search and development service, North of England
commissioning support unit, Avon primary care collab-
orative, Lincolnshire community health services NHS
trust, clinical research network: North West Coast clin-
ical commissioning group, Norfolk & Suffolk primary &
community care research office, Leicester City clinical
commissioning group, South London clinical research
network, West Midlands Primary Care RM&G business
support service and clinical research network: West
Midlands, research support team. The trial has been
allocated an International Standard Randomised Con-
trolled Trials Number (ISRCTN13762819).
Study sponsorship
Camden and Islington NHS Foundation Trust is the trial
sponsor.
Discussion
The PRIMROSE intervention has been developed using
evidence from the literature, focus groups and work-
shops with key stakeholders. The intervention is under-
pinned by a theoretical framework [36], which was applied
to the development work findings in order to select simple
behaviour change strategies that can be used by practice
nurses or HCAs, with minimal training, and incorporated
into time-limited primary care consultations.
Existing reviews identify a need for interventions that
tackle multiple cardiovascular risk factors in people with
SMI [60]. Many of the interventions that have been
tested in this group have been intensive behavioural in-
terventions for weight loss or smoking cessation, deliv-
ered in secondary care settings by research therapists
[61, 62]. The PRIMROSE study is a pragmatic trial with
the intervention being delivered by a practice nurse/
HCA at each participant’s GP practice. It may be pos-
sible to implement this model as part of routine clinical
primary care, for example, in a UK setting as part of an
Enhanced Service Model [63].
Offering cardiovascular risk lowering interventions to
people with severe mental illnesses may provide an oppor-
tunity for early intervention and prevention before cardio-
vascular events occur. Physical health checks for people
with SMI can be limited and are often opportunistic [33].
The PRIMROSE intervention seeks to address this issue,
offering intensive consultations over a 6-month period
that complement the clinical skills of practice nurses or
HCAs to manage multiple CVD risk factors.
The results will assess the impact of the intervention
on total cholesterol at 12-month follow-up. The impact
of the intervention on secondary outcomes of health be-
haviours, quality of life, well-being, medication adher-
ence, service use and medication prescriptions will be
measured. The cost effectiveness of the intervention will
also be determined.
Dissemination
We will disseminate the results of the study through so-
cial media, the Lived Experience Advisory Group and
through summary reports of findings to all key stake-
holders involved in the study.
Trial status
The trial is currently ongoing.
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